Impacts of intravitreal anti-VEGF therapy on retinal anatomy and neurophysiology in diabetic macular edema

被引:5
|
作者
Yozgat, Zubeyir [1 ]
Dogan, Mustafa [1 ]
Sabaner, Mehmet Cem [1 ]
Gobeka, Hamidu Hamisi [2 ]
Yazgan Akpolat, Serpil [3 ]
机构
[1] Afyonkarahisar Hlth Sci Univ, Afyon, Turkey
[2] Ibrahim Cecen Univ Agri, Agri Merkez, Turkey
[3] Malatya Inonu Univ, Malatya, Turkey
关键词
Aflibercept; Diabetic macular edema; Fundus fluorescein angiography; Microperimetry; Multifocal electroretinography; Optical coherence tomography;
D O I
10.1007/s10792-021-01737-w
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To evaluate anatomical and neuroretinal functional aspects in patients with diabetic macular edema (DME) after intravitreal anti-vascular endothelial growth factor (VEGF) therapy, in particular aflibercept. Materials and methods This prospective single-centered interventional study was performed at Afyonkarahisar Health Science University Faculty of Medicine, Department of Ophthalmology, where 32 eyes of 32 patients with DME were investigated. All patients received five intravitreal aflibercept injections on a monthly basis and were followed up for >= 6 months. After a comprehensive ophthalmological examination, including the measurements of visual acuity and intraocular pressure, and an antero-posterior segment slit-lamp biomicroscopy before and after full pupil dilation, fundus fluorescein angiography and optical coherence tomography were performed at baseline and during the third and sixth months post-therapy. Microperimetry and multifocal electroretinography were also performed at baseline and during the sixth months. Results Mean visual acuity increased from 0.73 to 0.57 and 0.33 logarithm of the minimum angle of resolution (logMAR) during the third and sixth months, respectively (p < 0.001). Changes in intraocular pressure were not statistically significant (p = 0.472). There was statistically significantly decreased mean central macular thickness from 390.2 mu m to 242.6 and 289.7 mu m during the third and sixth months, respectively (p < 0.001). Significantly improved fixation patterns during the sixth month, along with significantly increased macular sensitivity from 8.2 to 14.2 dB (p < 0.001) and significantly decreased local deficit from - 10.3 to 5.5 dB (p < 0.001) were observed. Further, there was a significantly increased N1 amplitude in the first ring and significantly increased P1 amplitude in all rings (p for each parameter < 0.05). There was also significantly decreased N1 wave implicit time in all rings and significantly decreased P1 wave in the second, third, fourth and fifth rings (p for each parameter < 0.05). Conclusions Patients with DME showed profound improvement in the retinal neurophysiological function, which was also accompanied by anatomical and ultrastructural integrity recovery after intravitreal aflibercept therapy. In the pathogenesis of DME, the influence of neurodegeneration has been increasingly gaining significant attention. Consequently, the need to assess neurophysiological effects of anti-VEGF therapy using a variety of diagnostic measures like electrophysiological studies and multimodal imaging technologies is undeniably growing.
引用
收藏
页码:1783 / 1798
页数:16
相关论文
共 50 条
  • [41] Latest News Anti-VEGF for diabetic Macular Edema
    不详
    SPEKTRUM DER AUGENHEILKUNDE, 2011, 25 (04) : 281 - 281
  • [42] Anti-VEGF Molecules for the Management of Diabetic Macular Edema
    Bandello, Francesco
    Cicinelli, Maria Vittoria
    Parodi, Maurizio Battaglia
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (32) : 4731 - 4737
  • [43] Comparison of the efficacy of intravitreal Anti-VEGF versus intravitreal dexamethasone implant in treatment resistant diabetic Macular Edema
    Hakan Koc
    Atilla Alpay
    Suat Hayri Ugurbas
    BMC Ophthalmology, 23
  • [44] Fellow eye effect of unilateral intravitreal anti-VEGF injections in eyes with diabetic macular edema
    Hanhart, J.
    Chowers, I.
    EYE, 2015, 29 (02) : 292 - 293
  • [45] OCT Predictors for BCVA Response to Intravitreal anti-VEGF Treatment in Eyes with Diabetic Macular Edema
    Santos, Ana Rita
    Schwartz, Christian
    Simao, Silvia N.
    Costa, Miguel
    Alves, Dalila
    Ribeiro, Maria Luisa
    Figueira, Joao
    Cunha-Vaz, Jose G.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [46] OCT Predictors for BCVA Response to Intravitreal Anti-VEGF Treatment in Eyes with Diabetic Macular Edema
    Santos, Ana Rita
    Costa, Miguel
    Schwartz, Christian
    Alves, Dalila
    Figueira, Joao
    Silva, Rufino
    Cunha-Vaz, Jose
    OPHTHALMOLOGICA, 2016, 236 : 45 - 45
  • [47] Intraocular Pressure Trends Following Intravitreal Injections of Anti-VEGF Agents for Diabetic Macular Edema
    Al-Abdullah, Abdulelah
    Nowilaty, Sawsan
    Ghazi, Nicola
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [48] Comparison of the efficacy of intravitreal Anti-VEGF versus intravitreal dexamethasone implant in treatment resistant diabetic Macular Edema
    Koc, Hakan
    Alpay, Atilla
    Ugurbas, Suat Hayri
    BMC OPHTHALMOLOGY, 2023, 23 (01)
  • [49] Fellow eye effect of unilateral intravitreal anti-VEGF injections in eyes with diabetic macular edema
    J Hanhart
    I Chowers
    Eye, 2015, 29 : 292 - 293
  • [50] Evaluation of outer retinal tubulations in diabetic macular edema underwent anti-VEGF treatment
    Xiao-Li Huang
    Yan-Ping Song
    Qin Ding
    Xiao Chen
    Ling Hong
    International Journal of Ophthalmology, 2019, (03) : 442 - 450